New Search

Export article

Minimal change disease following the Moderna mRNA-1273 SARS-CoV-2 vaccine

Amy Holzworth, Patrick Couchot, Wanda Cruz-Knight,
Published: 25 May 2021

Abstract: The immunologic response following several varieties of vaccination has been described as a potential trigger for the development of both de novo as well as recurrent minimal change (MCD) disease (1Gutiérrez S. Dotto B. Petiti J.P. et al.Minimal change disease following influenza vaccination and acute renal failure: just a coincidence?.Nefrologia. 2012 May 14; 32: 414-415PubMed Google Scholar). There have been emerging cases, including that described by Kervella et al. of MCD shortly after vaccination with the BNT162b2 vaccine (Pfizer-BioNTech) (2Lebedev L. Sapojnikov M. Wechsler et al.Minimal change disease following the Pfizer-BioNTech COVID-19 Vaccine.American Journal of Kidney Diseases. 2021 Apr 8; (S0272-6386(21)00509-6)Abstract Full Text Full Text PDF PubMed Scopus (0) Google Scholar, 3Kervella D. Jacquemont L. Chapelet-Debout A. et al.Minimal change disease relapse following SARS-CoV2 mRNA vaccine.Kidney Int. 2021 May 5; (S0085-2538(21)00478-6)Abstract Full Text Full Text PDF PubMed Google Scholar). We report to the best of the author’s knowledge the first case of minimal change disease presenting as nephrotic syndrome following the Moderna mRNA-1273 SARS-CoV-2 vaccine.
Keywords: vaccine / Full Text / PDF / BioNTech / Pfizer / SARS / Minimal change disease

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

Share this article

Click here to see the statistics on "Kidney International" .
References (3)
    Cited by 3 articles
      Back to Top Top